- Home
- SRG vs BDTX Comparison
SRG vs BDTX Comparison
Compare SRG & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | BDTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.5M | 104.0M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SRG | BDTX |
|---|---|---|
| Price | $1.58 | $1.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 135.0K | ★ 610.9K |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.90 | ★ 130.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,204,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.30 | N/A |
| 52 Week Low | $1.55 | $1.60 |
| 52 Week High | $4.38 | $4.94 |
Technical Indicators
Market Signals| Indicator | SRG | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.21 | 47.14 |
| Support Level | $1.57 | $1.79 |
| Resistance Level | $2.08 | $1.93 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 14.52 | 61.11 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.